title: Overexpression of the toll-like receptor (TLR) signaling adaptor MYD88, but lack of genetic mutation, in myelodysplastic syndromes.
abstract: MYD88 is a key mediator of Toll-like receptor innate immunity signaling. Oncogenically active MYD88 mutations have recently been reported in lymphoid malignancies, but has not been described in MDS. To characterize MYD88 in MDS, we sequenced the coding region of the MYD88 gene in 40 MDS patients. No MYD88 mutation was detected. We next characterized MYD88 expression in bone marrow CD34+ cells (N = 64). Increased MYD88 RNA was detected in 40% of patients. Patients with higher MYD88 expression in CD34+ cells had a tendency for shorter survival compared to the ones with lower MYD88, which was significant when controlled for IPSS and age. We then evaluated effect of MYD88 blockade in the CD34+ cells of patients with lower-risk MDS. Colony formation assays indicated that MYD88 blockade using a MYD88 inhibitor resulted in increased erythroid colony formation. MYD88 blockade also negatively regulated the secretion of interleukin-8. Treatment of MDS CD34+ cells with an IL-8 antibody also increased formation of erythroid colonies. These results indicate that MYD88 plays a role in the pathobiology of MDS and may have prognostic and therapeutic value in the management of patients with this disease.
authors: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
authors: Sophie
authors: S
authors: Dimicoli
authors: Yue
authors: Y
authors: Wei
authors: Carlos
authors: C
authors: Bueso-Ramos
authors: Hui
authors: H
authors: Yang
authors: Courtney
authors: C
authors: Dinardo
authors: Yu
authors: Y
authors: Jia
authors: Hong
authors: H
authors: Zheng
authors: Zhihong
authors: Z
authors: Fang
authors: Martin
authors: M
authors: Nguyen
authors: Sherry
authors: S
authors: Pierce
authors: Rui
authors: R
authors: Chen
authors: Hui
authors: H
authors: Wang
authors: Chenghua
authors: C
authors: Wu
authors: Guillermo
authors: G
authors: Garcia-Manero
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000906:Antibodies / Q000494:pharmacology; D018952:Antigens, CD34 / Q000235:genetics / Q000378:metabolism; D005260:Female; D005786:Gene Expression Regulation; D006801:Humans; D016209:Interleukin-8 / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009190:Myelodysplastic Syndromes / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D053594:Myeloid Differentiation Factor 88 / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism; D010455:Peptides / Q000494:pharmacology; D017422:Sequence Analysis, DNA; D015398:Signal Transduction; D016019:Survival Analysis; D051193:Toll-Like Receptors / Q000235:genetics* / Q000378:metabolism
chemical_list: D000906:Antibodies; D018952:Antigens, CD34; D016209:Interleukin-8; C507779:MYD88 protein, human; D053594:Myeloid Differentiation Factor 88; D010455:Peptides; D051193:Toll-Like Receptors
references: J Immunol. 2011 May 1;186(9):5367-75
references: 21441445
references: Leuk Res. 2010 Apr;34(4):507-12
references: 19913910
references: Science. 1978 Jun 9;200(4346):1153-4
references: 306682
references: J Clin Invest. 2000 Jul;106(2):263-70
references: 10903342
references: Trends Biochem Sci. 2002 Sep;27(9):474-82
references: 12217523
references: Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8811-6
references: 12857954
references: J Clin Oncol. 2012 Sep 20;30(27):3376-82
references: 22869879
references: Cell. 2007 Sep 21;130(6):1083-94
references: 17825402
references: N Engl J Med. 2009 Nov 5;361(19):1872-85
references: 19890130
references: J Biol Chem. 2006 Jan 20;281(3):1652-9
references: 16293622
references: Leukemia. 2013 Nov;27(11):2177-86
references: 23538751
references: Oncogene. 2009 Feb 26;28(8):1099-109
references: 19079347
references: Leukemia. 2013 Sep;27(9):1832-40
references: 23765228
references: Eur J Immunol. 2010 Feb;40(2):505-15
references: 19950169
references: Infect Immun. 2001 Apr;69(4):2270-6
references: 11254583
references: Dev Cell. 2005 Jan;8(1):109-16
references: 15621534
references: Clin Cancer Res. 2007 Feb 15;13(4):1154-60
references: 17317824
references: Leuk Res. 1999 Aug;23(8):741-9
references: 10456672
references: J Biol Chem. 2005 Apr 22;280(16):15809-14
references: 15755740
references: PLoS One. 2010 Mar 02;5(3):e9496
references: 20209110
references: Hematol Oncol Clin North Am. 2010 Apr;24(2):343-59
references: 20359630
references: Proc Natl Acad Sci U S A. 1995 Oct 10;92(21):9623-7
references: 7568185
references: Eur J Haematol. 2012 Mar;88(3):273-4
references: 21991928
references: Nature. 2011 Feb 3;470(7332):115-9
references: 21179087
references: Immunity. 2006 Jun;24(6):801-812
references: 16782035
references: N Engl J Med. 2012 Aug 30;367(9):826-33
references: 22931316
references: Blood. 2011 Oct 27;118(17):4666-73
references: 21873545
references: J Immunol. 2001 Nov 15;167(10):5887-94
references: 11698465
references: Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):652-6
references: 18178624
references: Cell. 2006 Feb 24;124(4):783-801
references: 16497588
references: Nature. 2011 Jun 05;475(7354):101-5
references: 21642962
references: Blood. 2012 Jul 26;120(4):858-67
references: 22685174
references: J Immunol. 2005 Jul 1;175(1):494-500
references: 15972684
references: Oncogene. 2009 Dec 10;28(49):4353-63
references: 19826413
references: Cell Death Differ. 2006 May;13(5):816-25
references: 16410796
references: Cancer Cell. 2012 Oct 16;22(4):466-78
references: 23079657
references: Nat Med. 2010 Jan;16(1):49-58
references: 19898489